Planegg-Martinsried, Germany – Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of FYB203/AHZANTIVE®1 (aflibercept), Formycon’s biosimilar to Eylea®2, informed Formycon AG (FSE: FYB), that it has concluded an exclusive license agreement with Lotus Pharmaceutical (“Lotus”), a multinational pharmaceutical company, for the commercialization of FYB203/AHZANTIVE® in Asia-Pacific (“APAC”) countries: Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam as well as the Special Administrative Region Hong Kong. In parallel, Formycon has signed an agreement with Lotus under which Formycon will supply the finished product.

Lotus is a global pharmaceutical company with a strong presence in Asia and a diverse portfolio of novel, generic and biosimilar medicines. Upon signature of the agreement, Klinge will receive upfront payments and is eligible to receive milestone payments on launch and sales. Additionally, Klinge will receive royalties on Lotus’ net sales. Formycon will participate in all Klinge income in the mid-single to low-double-digit percentage range.

“We are extremely pleased to welcome Lotus as a strong partner with a unique presence in the APAC region. Formycon and Lotus share the ambition to improve access to affordable, high-quality medicines for patients worldwide. Together we look forward to making a relevant contribution to healthcare in the APAC region and providing AHZANTIVE® as an effective and cost-efficient treatment option for patients affected by serious retinal diseases,” says Nicola Mikulcik, CBO of Formycon AG.

“Lotus is proud to partner with Formycon and to add AHZANTIVE® (aflibercept), a biosimilar to Eylea®, to our product portfolio aimed at improving access to healthcare in the Asia-Pacific region,” says Petar Vazharov, CEO of Lotus. “Leveraging our regional expertise, we look forward to working closely with Formycon to deliver this impactful and much-needed treatment to healthcare providers and patients.”

In June 2024, the U.S. Food and Drug Administration (FDA) approved the aflibercept biosimilar FYB203. Approval by the European Commission followed in January 2025. Formycon and Lotus closely align to prepare the regulatory submissions in the APAC countries according to the local requirements.

Eylea® (Aflibercept) is used to treat neovascular age-related macular degeneration (nAMD) and other severe retinal diseases. The active ingredient inhibits vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.



1) AHZANTIVE® is a registered trademark of Klinge Biopharma GmbH
2) Eylea® is a registered trademark of Regeneron Pharmaceuticals Inc.